NSWRC(600165)
Search documents
宁科生物(600165) - 2016 Q2 - 季度财报
2016-08-30 16:00
Financial Performance - The company's operating revenue for the first half of 2016 was CNY 1,593,397,257.60, representing a 317.06% increase compared to CNY 382,056,483.98 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was a loss of CNY 53,421,339.49, an improvement from a loss of CNY 58,218,083.29 in the previous year[24]. - The net cash flow from operating activities was negative CNY 41,927,809.82, a decrease of 132.26% compared to a positive cash flow of CNY 129,981,731.56 in the same period last year[24]. - The total assets at the end of the reporting period were CNY 4,060,129,800.20, an increase of 3.50% from CNY 3,922,652,843.69 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 6.04% to CNY 905,233,575.70 from CNY 963,408,720.36 at the end of the previous year[24]. - Basic earnings per share for the first half of 2016 were CNY -0.078, compared to CNY -0.213 in the same period last year[24]. - The weighted average return on net assets was -5.707%, an improvement from -6.529% in the previous year[24]. - The company achieved operating revenue of CNY 1,593.40 million, a significant increase of 317.06% compared to the previous year[30]. - The net profit attributable to shareholders was CNY -53.42 million, indicating a loss during the reporting period[30]. - The company reported a net cash flow from operating activities of CNY -41.93 million, a decline of 132.26% year-on-year[33]. - The company reported a significant increase in prepayments to CNY 131,672,784.99 from CNY 42,164,822.34, representing a growth of about 212.5%[84]. - The company reported a comprehensive income of 58,955,292.59 for the current period, contributing positively to the overall equity[111]. Revenue and Sales - Domestic revenue reached CNY 1,557.32 million, up 334.86% from the previous year, driven by increased trade activities[39]. - The company’s subsidiary, Guomao Company, engaged in copper trading, generating revenue of CNY 1,235.60 million, contributing to the overall revenue growth[30]. - The company’s metal products sales volume was 55,400 tons, achieving 42.62% of the annual target of 130,000 tons[35]. - Sales revenue from goods and services received was 2,033,228,366.47 RMB, a substantial increase from 573,337,032.81 RMB in the previous period[98]. Investments and Assets - The company holds a 9.55% stake in Huanghe Bank, resulting in an investment income of CNY 19.62 million during the reporting period[33]. - The company holds a 9.55% stake in Huanghe Bank, with a book value of approximately CNY 464.68 million and recognized investment income of CNY 19.62 million during the reporting period[44]. - Huanghe Bank reported a net profit of CNY 202.40 million for the reporting period, contributing to the company's investment income[44]. - The company's long-term equity investments stood at CNY 464,683,053.22, a marginal increase from CNY 461,684,688.76[84]. - The total amount of other receivables at the end of the period is CNY 25,066,145.80, with a bad debt provision of CNY 1,759,688.46, representing 7.02% of the total[200]. Research and Development - R&D expenses increased by 109.05% to CNY 3.14 million, reflecting the company's commitment to innovation[33]. - The company has developed over ten core technologies in metal products, including pre-tensioning technology and optimized design for steel wire rope, filling domestic gaps and achieving breakthroughs in large-tonnage pre-tensioning technology[41]. - The company holds 5 utility model patents and has registered software copyrights for logistics management systems related to steel wire rope production[41]. Corporate Governance and Structure - The company did not implement any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[6]. - There were no non-operating fund occupation situations by controlling shareholders and their related parties[8]. - The company has approved related party transactions, including sales of electrolytic copper and bank acceptance bills[53]. - The company completed the acquisition of a 30% stake in Jiangsu Boya Stem Cell Technology Co., Ltd.[54]. - The total number of shareholders reached 31,536 by the end of the reporting period[71]. - Shanghai Zhongneng Enterprise Development (Group) Co., Ltd. holds 200,000,000 shares, accounting for 29.20% of total shares[72]. - The company experienced no changes in controlling shareholders or actual controllers during the reporting period[74]. - Four independent directors resigned after completing their six-year terms, while four new independent directors were appointed[79]. Financial Position and Liabilities - The company's total liabilities reached CNY 3,087,620,599.00, compared to CNY 2,890,438,452.86, marking an increase of around 6.8%[86]. - The total owner's equity decreased to CNY 972,509,201.20 from CNY 1,032,214,390.83, a decline of approximately 5.8%[86]. - The total guarantee amount (including guarantees to subsidiaries) is 37,599.40 million, accounting for 40.77% of the company's net assets[58]. - The total guarantee amount to subsidiaries during the reporting period is 22,329.40 million, with a year-end balance of 23,399.40 million[58]. - The company has multiple guarantees with amounts ranging from 125 million RMB to 2,500 million RMB, all set to expire in 2016[57]. Accounting Policies and Compliance - The company has not changed its accounting policies or estimates during the reporting period[65]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements reflect the true financial condition and operating results[123]. - The company’s accounting policies and estimates are based on actual transactions and events, ensuring compliance with relevant regulations[121]. - The company recognizes liabilities for retirement benefits and severance payments based on obligations incurred, with severance payments discounted if payable beyond one year[165]. Future Outlook and Risks - The report includes a risk statement regarding forward-looking statements, indicating that future plans and strategies do not constitute a substantive commitment to investors[7]. - The company anticipates a significant change in cumulative net profit compared to the same period last year[51]. - There are no warnings regarding potential losses or significant changes in net profit for the upcoming reporting period[51]. - Future outlook and guidance were not explicitly mentioned, suggesting a potential area for further clarification in upcoming communications[97].
宁科生物(600165) - 2015 Q4 - 年度财报
2016-05-13 16:00
Financial Performance - In 2015, the company's operating revenue was CNY 1,076,651,547.45, a decrease of 19.84% compared to CNY 1,343,165,677.31 in 2014[20] - The net profit attributable to shareholders was CNY 46,088,660.78, a significant recovery from a loss of CNY 107,963,614.24 in 2014[20] - The basic earnings per share for 2015 was CNY 0.067, recovering from a loss of CNY 0.394 in 2014[21] - The company reported a net profit attributable to shareholders of RMB 46,088,660.78 for the year 2015, a significant recovery from a loss of RMB 107,963,614.24 in 2014[82] - The net profit for 2015 was CNY 47,165,215.71, a significant recovery from a net loss of CNY 114,082,334.80 in the previous year[185] Assets and Liabilities - The company's total assets increased by 63.39% to CNY 3,922,652,843.69 at the end of 2015, compared to CNY 2,400,794,698.54 at the end of 2014[20] - The total liabilities increased to CNY 2,507,302,492.33, up from CNY 1,024,120,158.39, indicating a rise of approximately 144.5%[182] - The total equity attributable to shareholders was CNY 963,408,720.36, compared to CNY 920,783,885.27 at the beginning of the year, reflecting a modest increase of approximately 4.6%[179] - The company's total liabilities reached CNY 2,890,438,452.86, up from CNY 1,476,468,804.51, indicating a significant increase of about 96.5%[178][179] Cash Flow - The net cash flow from operating activities was CNY -234,800,343.97, slightly improved from CNY -241,897,813.04 in 2014[20] - The company experienced a net cash flow from operating activities of RMB 152,781,832.94 in the first quarter, but faced a negative cash flow of RMB -423,201,184.10 in the fourth quarter, indicating volatility in cash management[24] - Cash flow from operating activities showed a net outflow of ¥234,800,343.97, slightly improved from a net outflow of ¥241,897,813.04 in the previous year[192] Investments and Acquisitions - The company sold 100% equity and debt of its subsidiary Shanghai Zhongshang Industrial Co., Ltd., and acquired 80% equity of Boya Stem Cell[35] - The company’s investment activities generated a net cash outflow of CNY 997,665,594.46, primarily due to the acquisition of Boya Stem Cell[43] - The company has acquired 80% of Boya Stem Cells, transitioning to a dual-main business model in metal products and biotechnology[74] Market Position and Strategy - The company is one of the largest manufacturers of steel wire ropes in China, with over 70 product varieties and 1,500 specifications, maintaining a leading position in the domestic market[30] - The domestic steel wire rope industry is characterized by an oversupply of low-tech products, while high-tech, high-value products remain in short supply, indicating a market opportunity for the company[31] - The company plans to enhance production efficiency and increase the sales proportion of high-value-added products to maintain competitive advantages in the steel wire rope industry[71] - The company plans to focus on expanding its market presence and enhancing product development strategies moving forward[189] Research and Development - The company’s R&D expenditure decreased by 32% to CNY 2,153,006.34, indicating reduced investment in innovation[42] - R&D investment totaled ¥8.874 million, with 12 technology projects implemented[55] - The company plans to enhance its research and development capabilities and explore new investment areas to seek further growth[75] Governance and Compliance - The company has committed to fair and reasonable transactions with related parties, adhering to market principles[84] - The company has ensured compliance with legal and regulatory requirements in its operations and transactions, safeguarding its reputation[85] - The company has established a system for managing insider information to prevent insider trading and ensure fair information disclosure[153] Shareholder Information - The company has implemented a cash dividend policy to ensure stable returns for investors while maintaining sustainable development[80] - The company did not implement a profit distribution for 2015 due to a cumulative profit available for distribution of CNY -14,104,891.94[5] - The total number of shareholders at the end of the reporting period was 30,524, down from 34,030 at the end of the previous month[119] Employee and Management - The total number of employees in the parent company is 1,922, while the total number of employees in major subsidiaries is 1,041, resulting in a combined total of 2,963 employees[146] - The total compensation for senior management at the end of the reporting period amounted to 3.111 million yuan[143] - The company has implemented a performance-based salary system for senior management, combining a basic annual salary with a performance bonus[143] Risks and Challenges - The company faced significant risks as detailed in the board report, which investors are advised to review[6] - The company faces risks from intense competition in the metal products industry and fluctuating raw material prices affecting production costs[76] - The stem cell industry is experiencing increased regulatory scrutiny, which may impact the approval of clinical applications and treatments[77]
宁科生物(600165) - 2016 Q1 - 季度财报
2016-04-29 16:00
Financial Performance - Operating revenue surged by 284.76% to CNY 639,301,901.39 year-on-year[6] - Net profit attributable to shareholders was a loss of CNY 20,106,206.17, an improvement from a loss of CNY 32,307,506.76 in the same period last year[6] - Operating revenue increased to $639.30 million, up 284.76% from $166.15 million in the same period last year[13] - The net loss for Q1 2016 was ¥19,158,310.66, compared to a net loss of ¥32,299,735.42 in Q1 2015, showing an improvement of approximately 40.6%[34] - The company reported an operating profit of -¥18,669,099.18 for Q1 2016, an improvement from -¥34,910,419.21 in Q1 2015[34] Cash Flow - Cash flow from operating activities showed a negative net amount of CNY 32,690,687.06, a decline of 121.40% compared to the previous year[6] - Net cash flow from operating activities decreased to -$32.69 million, a decline of 121.40% compared to $152.78 million in the previous year[15] - The cash flow from operating activities shows a net outflow of -¥32,690,687.06, compared to a net inflow of ¥152,781,832.94 in the previous period[41] - Operating cash flow for Q1 2016 was negative at -29,214,579.96 RMB, a significant decrease from 137,716,240.88 RMB in the same period last year, reflecting a decline of approximately 121%[44] - The company’s cash flow from investment activities was negative at -2,494,545.79 RMB, compared to -231,823,610.43 RMB in the same period last year, showing an improvement of approximately 99%[44] Assets and Liabilities - Total assets increased by 5.20% to CNY 4,126,798,544.70 compared to the end of the previous year[6] - The company's current assets totaled CNY 1,414,239,843.33, up from CNY 1,207,447,820.62 at the start of the year, reflecting a growth of approximately 17.1%[24] - The total liabilities reached CNY 3,117,628,630.24, compared to CNY 2,890,438,452.86 at the beginning of the year, indicating an increase of approximately 7.9%[26] - The company's short-term borrowings rose to CNY 1,099,780,000.00 from CNY 914,760,000.00, marking an increase of about 20.2%[25] - The company's total liabilities increased to ¥2,606,998,816.94 from ¥2,507,302,492.33, marking a rise of approximately 4.0%[29] Shareholder Information - The number of shareholders reached 34,030, with the top ten shareholders holding a combined 78.12% of shares[9] - The company has committed to not engaging in competitive business activities with its main operations and ensuring the protection of minority shareholders' interests[19] Operational Costs - Operating costs rose to $607.27 million, reflecting a 295.36% increase from $153.60 million year-over-year[13] - Sales expenses increased to $20.98 million, a rise of 56.26% from $13.42 million year-over-year, primarily due to the consolidation of Boya Stem Cell Technology Co., Ltd.[14] - Management expenses rose to $16.98 million, an 18.00% increase from $14.39 million, also attributed to the consolidation of Boya Stem Cell Technology Co., Ltd.[14] Other Financial Metrics - The weighted average return on net assets was -0.021%, an improvement from -3.571% in the previous year[6] - The company recorded a total of CNY 414,408.44 in non-recurring gains and losses during the reporting period[7] - The company has not indicated any significant changes in its net profit forecast for the year compared to the previous year[21] - Basic and diluted earnings per share for Q1 2016 were both -¥0.029, compared to -¥0.118 in the same quarter last year, indicating a reduction in loss per share[35]
宁科生物(600165) - 2015 Q3 - 季度财报
2015-10-08 16:00
Financial Performance - Operating income decreased by 44.21% to CNY 644,416,538.52 for the first nine months compared to the same period last year[7] - Net profit attributable to shareholders was CNY -17,336,260.46, showing a significant decline from CNY -6,595,482.32 in the previous year[7] - Operating revenue decreased to ¥644,416,538.52, down 44.21% from ¥1,154,997,326.90 in the same period last year[14] - Total revenue for the third quarter was CNY 262,360,054.54, a decrease of 37.9% compared to CNY 422,594,010.02 in the same period last year[34] - The company's net profit for the first nine months was CNY 93,687,114.86, compared to CNY 86,741,881.48 in the same period last year, reflecting a year-over-year increase of 8.5%[34] - Net profit for Q3 2015 reached ¥50,574,265.10, compared to a net loss of ¥19,819,125.89 in Q3 2014[40] - Total profit for Q3 2015 was ¥50,574,265.10, significantly improving from a loss of ¥23,316,618.69 in the same period last year[39] Cash Flow - Net cash flow from operating activities increased by 252.52% to CNY 188,400,840.13 for the first nine months compared to the same period last year[7] - Operating cash flow for the period from January to September reached ¥188,400,840.13, a significant increase from ¥53,444,742.40 in the same period last year, representing a growth of approximately 252.5%[43] - Total cash inflow from operating activities was ¥1,009,361,220.16, compared to ¥1,559,811,939.48 in the previous year, indicating a decrease of about 35.2%[43] - Cash outflow from operating activities totaled ¥820,960,380.03, down from ¥1,506,367,197.08 year-on-year, a reduction of approximately 45.5%[43] - Net cash flow from investing activities decreased to -¥64,483,049.89, a decline of 190.70% compared to -¥22,181,746.47 last year[16] - The net cash flow from financing activities was ¥46,839,524.64, a turnaround from -¥42,953,705.97 in the same period last year[44] Assets and Liabilities - Total assets increased by 5.42% to CNY 2,530,852,913.63 compared to the end of the previous year[7] - The company's total liabilities reached CNY 1,599,204,918.45, compared to CNY 1,476,468,804.51 at the beginning of the year, marking an increase of about 8.3%[27] - Short-term borrowings increased due to increased bank loans and reclassification of discounted notes[12] - The company's current assets totaled CNY 1,406,022,084.08, up from CNY 1,127,230,025.26 at the beginning of the year, indicating a significant increase of about 24.7%[25] - The company's total equity amounted to CNY 931,647,995.18, slightly up from CNY 924,325,894.03, showing a marginal increase of about 0.3%[27] Shareholder Information - The number of shareholders reached 10,412 at the end of the reporting period[10] - The company reported a significant increase in minority shareholders' equity, which rose to ¥32,520,119.14, up 818.13% from ¥3,542,008.76[14] Investments and Subsidiaries - The company completed the sale of its wholly-owned subsidiary Shanghai Zhongzheng Industrial Co., Ltd. for ¥196,187,012.46, generating an investment income of ¥77,081,400.00[20] - The company plans to increase its stake in Ningxia Huahui Activated Carbon Co., Ltd. by up to 6,304 million shares, currently holding 60.21%[17] Inventory and Receivables - The company's inventory stood at CNY 407,213,890.65, up from CNY 385,969,185.42, which is an increase of about 5.3%[25] - Accounts receivable increased to CNY 376,667,720.18 from CNY 337,841,475.95, representing a growth of approximately 11.5%[25]
宁科生物(600165) - 2015 Q2 - 季度财报
2015-08-28 16:00
Financial Performance - The company's operating revenue for the first half of 2015 was ¥382,056,483.98, a decrease of 47.84% compared to ¥732,403,316.88 in the same period last year[21]. - The net profit attributable to shareholders was a loss of ¥58,218,083.29, representing a decline of 457.60% from a profit of ¥16,280,171.89 in the previous year[21]. - Basic earnings per share for the first half of 2015 were -¥0.213, a decrease of 461.02% compared to ¥0.059 in the same period last year[22]. - The weighted average return on net assets was -6.529%, a decrease of 8.086 percentage points from 1.557% in the previous year[22]. - The company reported a significant decline in sales volume and prices due to the sluggish coal and steel industries, impacting overall revenue[28]. - The company reported a net loss of ¥146,757,812.73 compared to a loss of ¥88,539,729.44 in the previous period[80]. - The comprehensive income for the current period is a loss of CNY 58,412,088.94, indicating a significant decline in profitability[99]. - The total equity at the end of the current period is CNY 881,918,265.14, down from 924,044,008.97 at the end of the previous period, reflecting a decrease of 4.56%[103]. Cash Flow - The net cash flow from operating activities increased by 302.16% to ¥129,981,731.56, compared to ¥32,321,283.18 in the same period last year[21]. - Operating cash inflow for the period was CNY 617,974,505.67, down 37.0% from CNY 980,197,023.69 in the previous period[93]. - Cash inflow from sales of goods and services was CNY 573,337,032.81, a decline from CNY 909,443,934.91 in the previous period[93]. - Cash outflow from investment activities totaled CNY 241,924,632.98, significantly higher than CNY 13,309,375.53 in the previous period[94]. - Cash inflow from financing activities was CNY 654,131,000.00, up from CNY 325,100,000.00 in the previous period[94]. - The ending cash and cash equivalents balance decreased to CNY 34,544,216.56 from CNY 117,078,264.15 in the previous period[94]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,484,589,672.04, an increase of 3.49% from ¥2,400,794,698.54 at the end of the previous year[21]. - Total liabilities increased to ¥1,618,971,185.28 from ¥1,476,468,804.51, marking an increase of approximately 9.6%[80]. - Current assets increased to ¥1,241,852,939.99 from ¥1,127,230,025.26, representing a growth of approximately 10.2%[78]. - Total equity attributable to shareholders decreased to ¥862,279,018.34 from ¥920,783,885.27, a decline of approximately 6.3%[80]. Shareholder Information - The company plans to increase its capital reserve by converting every 10 shares into 15 shares, resulting in a total share capital increase to 684,883,775 shares[5]. - The first major shareholder's equity was judicially auctioned, with Shanghai Zhongneng acquiring the company's shares[58]. - The first major shareholder, Shanghai Zhongneng, holds 80 million shares, which are still under lock-up restrictions[64]. - The company guarantees not to harm the interests of minority shareholders during its normal production and operational activities[55]. Governance and Compliance - The company has established a governance structure in compliance with relevant laws and regulations, with no significant discrepancies noted[57]. - The company has committed to not utilizing its controlling position to harm the interests of the company and its minority shareholders[55]. - The financial report indicates that the company is in compliance with auditing requirements, as an audit report is applicable[76]. - The company has not reported any changes in accounting policies or significant errors during the reporting period[58]. Investment and Capital Structure - The investment income decreased by ¥68,730,000 due to the previous year's sale of shares in Lanzhou Bank, which generated an investment income of ¥87,160,000[28]. - The company acquired 703,300 shares of Huanghe Bank, increasing its total holdings to 138,481,513 shares, representing 9.55% of the bank's total equity[39][40]. - The total amount of guarantees provided by the company, including those to subsidiaries, is 53,269,000 RMB, which accounts for 60.37% of the company's net assets[52]. Accounting Policies - The financial statements are prepared in accordance with the relevant accounting standards, with the reporting currency being Renminbi[77]. - The company recognizes the operating results and cash flows of subsidiaries from the beginning of the reporting period in which they are consolidated[118]. - The company follows specific accounting treatments for mergers and acquisitions, including the recognition of goodwill when the acquisition cost exceeds the fair value of identifiable net assets[116]. - The company employs a systematic approach to assess and recognize bad debts, ensuring financial statements reflect accurate receivable values[132]. Inventory and Receivables - The ending balance of inventory is RMB 452,897,158.60, with a decrease of RMB 9,630,939.55 during the period[196]. - The company's accounts receivable at the end of the period amounted to ¥392,775,672.27, with a bad debt provision of ¥29,715,154.29, representing 7.57% of the total[177]. - The total amount of receivable dividends was ¥18,007,612.44 at the end of the period[184].
宁科生物(600165) - 2015 Q1 - 季度财报
2015-04-28 16:00
Financial Performance - Net profit attributable to shareholders decreased by 154.50% to a loss of CNY 32,307,506.76 compared to the same period last year[7] - Operating revenue decreased by 53.44% to CNY 166,154,435.96 compared to the previous year[7] - Basic earnings per share decreased by 154.63% to a loss of CNY 0.118 compared to the previous year[7] - The company reported a net loss of CNY -113,613,239.94 compared to CNY -88,539,729.44 at the beginning of the year, indicating a worsening of approximately 28.3%[24] - Total operating revenue for Q1 2015 was ¥166,154,435.96, a decrease of 53.4% compared to ¥356,823,514.80 in the same period last year[31] - The net profit for Q1 2015 was a loss of ¥32,299,735.42, compared to a profit of ¥58,226,644.23 in Q1 2014, representing a significant decline[31] - The company reported a total profit loss of ¥33,227,708.25 for Q1 2015, compared to a profit of ¥65,360,195.00 in the previous year[31] Cash Flow - Net cash flow from operating activities increased by 682.91% to CNY 152,781,832.94 compared to the same period last year[7] - Cash flow from operating activities for Q1 2015 was ¥152,781,832.94, a substantial increase from ¥19,514,643.33 in Q1 2014[39] - Operating cash flow for Q1 2015 was CNY 137,716,240.88, a significant improvement compared to a net outflow of CNY 15,407,623.61 in the same period last year[42] - Total cash inflow from financing activities was CNY 178,000,000.00, up from CNY 65,000,000.00 in the previous year[42] - Net cash flow from financing activities was CNY 66,094,143.76, compared to a net outflow of CNY 17,115,325.87 in the prior year[43] - Total cash outflow from operating activities was CNY 183,095,163.67, down from CNY 219,629,158.09 in the previous year[42] - The net increase in cash and cash equivalents was CNY -28,013,225.79, compared to a decrease of CNY -18,825,348.27 in the same period last year[43] Assets and Liabilities - Total assets increased by 4.13% to CNY 2,499,847,646.72 compared to the end of the previous year[7] - Current assets rose to CNY 1,240,532,734.01, up from CNY 1,127,230,025.26, indicating an increase of about 10%[22] - Total liabilities increased to CNY 1,600,713,054.26 from CNY 1,476,468,804.51, indicating a growth of about 8.4%[24] - Owner's equity decreased to CNY 899,134,592.46 from CNY 924,325,894.03, a decline of approximately 2.7%[24] - Long-term borrowings decreased by 100% to CNY 30,000,000.00, indicating a complete repayment[16] Operational Metrics - The company experienced a decrease in sales volume and prices, leading to reduced operating income and costs[14] - The company’s operating costs decreased by 53.05% to CNY 153,598,553.24 from CNY 327,141,416.40 in the previous year[16] - The company’s sales expenses decreased by 33.69% to CNY 13,423,187.61 from CNY 20,243,894.67 in the same period last year[16] - The company incurred financial expenses of ¥19,450,573.18 in Q1 2015, up from ¥15,865,294.67 in the same period last year[31] Shareholder Information - The number of shareholders increased to 16,453 at the end of the reporting period[10] - The company is facing uncertainty regarding the payment of the auction price and commission for the judicial auction of its largest shareholder's equity, which may lead to a change in the major shareholder[17] - The company has committed to avoiding competition with its major shareholder and related parties to reduce and regulate related transactions[18] Other Financial Activities - The company received government subsidies amounting to CNY 1,535,674.36, contributing to increased non-operating income[8] - The company reported a significant increase in prepayments due to increased advance payments by its subsidiary[13] - Prepayments increased by 258.29% to CNY 112,531,418.90 from CNY 31,407,673.22 at the beginning of the year[16] - The company’s other receivables increased by 58.13% to CNY 91,981,770.19 from CNY 58,168,316.99 at the beginning of the year[16] - The company reported a net cash outflow from investing activities of CNY -234,005,187.10, a significant decline compared to CNY 10,612,616.77 in the previous year, representing a decrease of 2,304.97%[16]
宁科生物(600165) - 2014 Q4 - 年度财报
2015-04-15 16:00
Financial Performance - In 2014, the company's operating revenue was CNY 1,343,165,677.31, a decrease of 23.85% compared to CNY 1,763,903,207.65 in 2013[26] - The net profit attributable to shareholders was a loss of CNY 205,902,327.73, compared to a loss of CNY 23,471,391.63 in the previous year, representing an increase in loss of 777.25%[26] - The net cash flow from operating activities was a loss of CNY 241,897,813.04, a significant decline from a positive cash flow of CNY 5,993,241.96 in 2013, marking a decrease of 4,136.18%[26] - Total assets at the end of 2014 were CNY 2,400,794,698.54, down 6.27% from CNY 2,561,362,498.61 at the end of 2013[26] - The company's net assets attributable to shareholders decreased by 10.55% to CNY 920,783,885.27 at the end of 2014[26] - The company's basic earnings per share for 2014 was -0.394 yuan, a decrease of 1,507.14% compared to 0.028 yuan in 2013[27] - The total revenue for the reporting period was 1,257,353,744.14 CNY, a decrease of 18.84% compared to the previous year[44] - The gross profit margin for metal products decreased by 10.55 percentage points, with total gross profit declining by 96.38 million yuan[32] - The company reported a net cash inflow from financing activities of 262,977,240.06 CNY, a significant increase compared to the previous period[52] - The company reported a net loss of CNY 114,082,334.80 for the year, compared to a profit of CNY 6,972,369.18 in 2013[178] Operational Changes - The company has maintained its main business without any changes since its listing[20] - The production of coal products decreased by 57.25%, with sales volume down by 37% due to the downturn in the coal industry[36] - New product development included military-grade steel wire rope, which successfully passed acceptance tests and was used in the Liaoning aircraft carrier[39] - The company integrated pre-sale, in-sale, and after-sale services, resulting in the acquisition of 800 tons of new market orders[40] - The company achieved a metal product sales volume of 169,900 tons, exceeding the annual plan by 2.35%[55] Research and Development - The company increased its research and development expenditure by 78.90% to 3,166,167.90 yuan in 2014[34] - Research and development expenses totaled 3,166,167.90 CNY, accounting for 0.34% of net assets and 0.24% of operating income[49] Shareholder and Governance - The company did not implement any profit distribution or capital reserve transfer to increase share capital for the year due to accumulated losses[4] - The company has implemented a cash dividend policy to enhance transparency and protect shareholder rights, with a three-year shareholder return plan established for 2012-2014[79] - The company reported a cash dividend of 0 RMB per 10 shares for the years 2012, 2013, and 2014, with net profits of 42,295,278.10 RMB, 7,612,001.80 RMB, and -107,963,614.24 RMB respectively, resulting in a dividend payout ratio of 0%[81] - The company has committed to avoid and reduce related party transactions with its major shareholders and controlling parties[92] - The company has established a training program to enhance employee quality awareness and operational skills[138] Risk Factors - The company has detailed risk factors in its report, advising investors to be cautious and aware of investment risks[5] - The company is facing significant risks due to intense competition in the metal products industry and fluctuating raw material prices affecting production costs[74] Social Responsibility - The company arranged employment for 103 disabled individuals and provided social insurance for them, demonstrating its commitment to social responsibility[82] - The company supported ecological migration projects by arranging jobs for 82 migrants and providing them with housing and daily necessities[82] - The company has actively participated in social welfare initiatives, including financial support for employees in need, with 245 employees receiving assistance totaling 64,420 RMB[82] Legal and Compliance - The company has been involved in significant legal issues, including the freezing of shares held by its major shareholder, Shanghai Xinri Equity Investment Co., Ltd.[85] - The company has not received any administrative penalties or public reprimands from the China Securities Regulatory Commission during the reporting period[97] - The company has improved its internal control management system in accordance with regulations from the Ministry of Finance and the China Securities Regulatory Commission[143] Financial Structure - The total amount of guarantees provided by the company, including those to subsidiaries, is 49,999.80 million RMB, which accounts for 54.11% of the company's net assets[90] - The total amount of guarantees provided during the reporting period (excluding those to subsidiaries) is 3,500.00 million RMB[90] - The company has no overdue guarantees and no violations reported[90] Management and Personnel - The company has a strong management team with diverse backgrounds in various industries[129] - The company employed a total of 2,730 staff, with 1,980 in the parent company and 750 in major subsidiaries[135] - The company’s senior management remuneration system includes a basic salary and performance-based salary[131] - There were changes in the board with several new appointments and resignations, including the hiring of two new directors[132] Market Presence - The company operates in the metal products industry, focusing on the production and sales of steel wires, steel ropes, and related products[198] - The company has expanded its market presence with 15 sales subsidiaries located across various cities in China[200]
宁科生物(600165) - 2014 Q3 - 季度财报
2014-10-28 16:00
Financial Performance - Operating revenue for the first nine months was CNY 1,154,997,326.90, representing a decline of 32.46% year-on-year[8] - Net profit attributable to shareholders was a loss of CNY 6,595,482.32, a decrease of 180.15% compared to the previous year[8] - Basic earnings per share were CNY -0.024, a decrease of 180.00% compared to the previous year[8] - The weighted average return on net assets was -0.64%, a decrease of 1.44 percentage points from the previous year[8] - Total operating revenue for Q3 2014 was ¥422,594,010.02, a decrease of 40% compared to ¥704,073,501.79 in Q3 2013[33] - The net loss for Q3 2014 was ¥22,886,007.03, compared to a net profit of ¥2,007,006.13 in Q3 2013[34] - Total profit for Q3 2014 was a loss of ¥23,316,618.69, compared to a profit of ¥3,218,573.57 in Q3 2013[38] - Net profit for the first nine months of 2014 was a loss of ¥19,819,125.89, compared to a profit of ¥2,735,787.52 in the same period last year[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,559,551,799.24, a decrease of 0.07% compared to the end of the previous year[8] - Current assets totaled ¥1,503,062,236.55, down from ¥1,543,391,273.92 at the start of the year, indicating a decrease of approximately 2.6%[23] - Total liabilities were reported at ¥1,479,738,590.22, slightly up from ¥1,474,087,905.81, indicating a marginal increase[25] - The company's equity totaled ¥1,079,813,209.02, down from ¥1,087,274,592.80, a decrease of approximately 0.4%[25] - The company’s non-current liabilities due within one year increased by 75.00% to CNY 35,000,000.00, reflecting an increase in long-term borrowings due within one year[13] - Total liabilities rose to ¥695,809,426.47, up from ¥623,025,302.66, indicating an increase of about 11.6%[30] Cash Flow - Cash flow from operating activities increased to CNY 53,444,742.40, up 302.91% year-on-year[8] - Net cash flow from operating activities increased by CNY 40,180,008.86 to CNY 53,444,742.40, mainly due to reduced cash payments for goods and increased advance receipts[16] - Cash inflow from borrowing amounted to $391 million, compared to $257.55 million in the previous period, indicating a significant increase[44] - Net cash flow from financing activities was $214,188.48, a recovery from a negative cash flow of $38.87 million in the prior period[44] - The ending balance of cash and cash equivalents decreased to $1.03 million from $8.81 million, reflecting a decline in liquidity[44] Investments - Long-term equity investments increased by 108.33% to CNY 176,454,509.91 due to the acquisition of shares in Ningxia Yellow River Rural Commercial Bank[13] - The company reported an investment income of 87.1638 million yuan from the transfer of 68.2 million shares of Lanzhou Bank[18] - Investment income surged by 5,496.25% to CNY 86,741,881.48, resulting from the transfer of shares in Lanzhou Bank[14] - The company completed the acquisition of 44.993517 million shares of Ningxia Yellow River Rural Commercial Bank from three individuals for a total transfer amount of 173.225041 million yuan[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 18,863[10] - The largest shareholder, Shanghai Xinri Equity Investment Co., Ltd., held 80,000,000 shares, accounting for 29.20% of the total shares, with all shares frozen[10] - The first major shareholder's stock has been subject to judicial freezing, impacting the company's stock liquidity[17] Government and Subsidies - The company reported a government subsidy of CNY 5,442,645.86, primarily related to its subsidiary Huahui Company[9] Financial Obligations - Cash outflow for debt repayment was $351 million, up from $272.85 million, showing increased financial obligations[44] - Cash dividends and interest payments totaled $39.79 million, compared to $23.57 million previously, indicating higher returns to shareholders[44] Operational Changes - The company is actively seeking to reduce and standardize related party transactions to protect the interests of other shareholders[20] - The company has committed to not transferring shares obtained from the non-public issuance of A shares for 36 months following the completion of the issuance[20] - The company has ongoing projects in construction, with capital expenditures reported at ¥29,930,386.62, up from ¥21,472,133.70[24]
宁科生物(600165) - 2014 Q2 - 季度财报
2014-08-07 16:00
Financial Performance - The company's operating revenue for the first half of 2014 was RMB 732,403,316.88, a decrease of 27.20% compared to the same period last year[17]. - The net profit attributable to shareholders for the first half of 2014 was RMB 16,280,171.89, representing an increase of 189.63% year-on-year[17]. - The basic earnings per share for the first half of 2014 was RMB 0.059, up 180.95% from RMB 0.021 in the same period last year[16]. - The weighted average return on net assets increased to 1.557% from 0.546% year-on-year, an increase of 1.011 percentage points[16]. - The net cash flow from operating activities was RMB 32,321,283.18, an increase of 15.43% compared to RMB 27,999,593.08 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was RMB -59,569,422.60, indicating a significant loss compared to RMB -7,091,899.98 in the previous year[17]. - The total operating income from the metal products segment was ¥476.25 million, with a gross margin of 4.83%, reflecting a decrease of 8.19 percentage points year-on-year[26]. - The total profit increased to ¥19,042,108.21 from ¥5,924,973.67, reflecting a growth of approximately 220.5% year-over-year[65]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 2,521,669,470.91, a decrease of 1.55% from RMB 2,561,362,498.61 at the end of the previous year[17]. - Total liabilities decreased from CNY 1,474,087,905.81 to CNY 1,418,555,848.13, a decline of approximately 3.78%[60]. - The company's total equity attributable to shareholders was 1,103,113,622.78 RMB at the end of June 2014, reflecting a decrease from 1,087,274,592.80 RMB at the end of the previous year[75]. - The total amount of other payables at the end of the period amounts to CNY 92,019,275.81, up from CNY 22,366,295.39 at the beginning of the period, representing an increase of approximately 312.5%[2]. - The total amount of social insurance payable at the end of the period is CNY 10,469,316.87, an increase from CNY 5,934,969.48 at the beginning of the period, reflecting a growth of approximately 77.5%[1]. Investments and Acquisitions - The company transferred 68.2 million shares of Lanzhou Bank, generating an investment income of ¥87.16 million[24]. - The company plans to acquire up to 10% of the shares of Ningxia Yellow River Rural Commercial Bank, with the purchase price based on the bank's net asset value from Q1 2014, increased by 10%[34]. - The company sold 40 million shares of Ruixin Source Import and Export Trading Co., generating a profit of 51.124 million RMB, contributing 268.47% to the total profit[36]. - The company sold 28.2 million shares of Longdong Agricultural Products Group, generating a profit of 36.041 million RMB, contributing 189.27% to the total profit[36]. Shareholder Information - The total number of shares before the change was 273,953,510, with 29.20% (80,000,000 shares) being restricted shares[45]. - The largest shareholder, Shanghai Xinri Equity Investment Co., Ltd., holds 29.20% of the shares, with 80,000,000 shares pledged and frozen[48]. - As of the end of the reporting period, the total number of shareholders was 24,273[48]. - The report indicates that there were no preferred shares issued during the reporting period[54]. Governance and Compliance - The company has established and improved its governance structure in accordance with relevant laws and regulations[43]. - The company has made commitments to avoid and reduce related party transactions, ensuring compliance with market principles[41]. - The company has not faced any administrative penalties or public reprimands from the China Securities Regulatory Commission during the reporting period[42]. - The company has not disclosed any major related party transactions during the reporting period[36]. Cash Flow and Financial Management - The cash flow from operating activities showed a decline of approximately 12.06% compared to the previous year, indicating operational challenges[73]. - The company plans to focus on improving cash flow management and exploring new investment opportunities to enhance financial stability moving forward[73]. - The total cash and cash equivalents at the end of the period were 38,760,963.81 RMB, down from 58,146,967.72 RMB at the end of the previous year[73]. - The company reported a significant increase in bank deposits, which rose to ¥104,825,124.49 from ¥40,734,592.85, indicating a growth of approximately 157.5%[153]. Inventory and Receivables - The inventory at the end of the period was valued at ¥300,316,641.47, with a provision for inventory depreciation of ¥4,267,603.85[169]. - The accounts receivable at the end of the period totaled ¥578,498,666.34, with a bad debt provision of ¥27,347,491.31, which is 4.73% of the total accounts receivable[157]. - The provision for bad debts for accounts receivable was 1.94% at the end of the period, compared to 2.41% at the beginning[164]. Taxation and Obligations - The total tax payable at the end of the period is CNY 2,773,477.95, compared to a tax receivable of CNY -3,006,247.24 at the beginning of the period, indicating a significant turnaround[1]. - The company has confirmed deferred tax assets related to deductible losses amounting to ¥978,374.46, down from ¥4,736,527.51 at the beginning of the period, indicating a significant decrease[183]. Operational Efficiency - The company is focused on expanding its market presence through the establishment of new subsidiaries in key regions[148]. - The report indicates a strong performance in sales across all subsidiaries, with consistent figures of 100% sales achievement[147][148]. - The company is actively pursuing new strategies for market expansion and product development in the wire rope sector[148].
宁科生物(600165) - 2014 Q1 - 季度财报
2014-04-29 16:00
Financial Performance - Net profit attributable to shareholders increased significantly by 1,600.06% to CNY 59,284,009.57 from CNY 3,487,173.24 in the same period last year[9] - Basic earnings per share increased to CNY 0.216 from CNY 0.013, representing a growth of 1,561.54%[9] - Operating profit for the current period is ¥64,383,538.00, compared to a loss of ¥6,388,126.06 in the previous period[30] - Net profit for the current period is ¥58,226,644.23, a significant increase from ¥2,234,487.77 in the previous period[30] - The company reported a total comprehensive income of ¥58,226,644.23 for the current period[31] Revenue and Costs - Operating revenue decreased by 1.12% to CNY 356,823,514.80 compared to CNY 360,852,681.65 in the previous year[9] - Total operating revenue for the current period is ¥356,823,514.80, a decrease of 1.4% from ¥360,852,681.65 in the previous period[30] - Total operating costs increased to ¥379,181,858.28, up 3.4% from ¥367,240,807.71 in the previous period[30] Cash Flow - Net cash flow from operating activities improved to CNY 19,514,643.33, a significant recovery from a negative CNY 23,958,345.74 in the same period last year[9] - Cash flow from operating activities generated a net amount of ¥19,514,643.33, compared to a negative cash flow of ¥23,958,345.74 in the previous period[38] - Cash inflow from investment activities totaled ¥18,593,200.00, while cash outflow was ¥7,980,583.23, resulting in a net cash flow of ¥10,612,616.77[38] - Cash inflow from financing activities was ¥71,000,000.00, an increase from ¥47,700,000.00 in the previous period[38] Assets and Liabilities - Total assets increased by 0.71% to CNY 2,579,524,772.44 compared to the end of the previous year[9] - Current assets rose to CNY 1,678,803,933.04, up from CNY 1,543,391,273.92, indicating an increase of about 8.7%[21] - Total liabilities decreased to CNY 1,433,875,212.27 from CNY 1,474,087,905.81, a decline of about 2.7%[22] - Shareholders' equity increased to CNY 1,145,649,560.17 from CNY 1,087,274,592.80, reflecting a growth of approximately 5.4%[23] Shareholder Information - The number of shareholders at the end of the reporting period was 25,913[10] - The largest shareholder, Shanghai Xinri Equity Investment Co., Ltd., holds 29.20% of the shares, totaling 80,000,000 shares[10] Investments and Other Income - The company recorded a gain of CNY 87,163,823.00 from the transfer of equity in Lanzhou Bank[9] - The company’s investment income remained stable at ¥86,741,881.48, indicating a consistent performance in this area[13] - The company reported a decrease in other income, which fell to ¥1,001,446.64, down by ¥8,673,298.55 or 89.65% from the previous year[13] Expenses - Sales expenses rose to ¥20,243,894.67, an increase of ¥5,495,949.64 or 37.27% compared to the previous year[13] - Financial expenses increased to ¥15,826,582.35, up by ¥5,805,027.92, reflecting a rise of 57.93% year-over-year[13] Future Plans and Challenges - The company plans to issue short-term financing bonds, which was approved by the board and shareholders[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30] - The company is facing significant litigation issues, including the freezing of shares held by the largest shareholder[16] - The company has committed to avoiding competitive activities with its major shareholders to reduce related party transactions[17]